# Orexigen Therapeutics, Inc.

Orexigen Therapeutics, Inc. is a company headquartered in La Jolla, CA, United States.

## Company overview

- **Legal name:** Orexigen Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** La Jolla, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001382911

## About

Orexigen Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001382911, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2017-03-30, it reported annual revenue of USD 33,709,000; net income of USD -24,524,000; total assets of USD 304,589,000 for the fiscal period ended 2016-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2016 (period ended 2016-12-31)

- **Revenue:** $33.7M (USD 33,709,000)
- **Net income:** -$24.5M (USD -24,524,000)
- **Total assets:** $304.6M (USD 304,589,000)
- **Cash and equivalents:** $92.5M (USD 92,494,000)

### FY2015 (period ended 2015-12-31)

- **Revenue:** $24.5M (USD 24,459,000)
- **Net income:** -$68.7M (USD -68,687,000)
- **Total assets:** $236.6M (USD 236,589,000)
- **Cash and equivalents:** $155.4M (USD 155,422,000)
- **Later filings:** Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2014 (period ended 2014-12-31)

- **Revenue:** $55.5M (USD 55,521,000)
- **Net income:** -$37.5M (USD -37,525,000)
- **Total assets:** $213.0M (USD 212,981,000)
- **Cash and equivalents:** $104.2M (USD 104,243,000)

### FY2013 (period ended 2013-12-31)

- **Revenue:** $3.4M (USD 3,428,000)
- **Net income:** -$77.7M (USD -77,671,000)
- **Total assets:** $180.1M (USD 180,121,000)
- **Cash and equivalents:** $98.1M (USD 98,121,000)
- **Operating cash flow:** -$70.8M (USD -70,817,000)

## Recent SEC filings

- Form 8-K — filed 2019-05-23 — period 2019-05-17 — 8-K
- Form 8-K — filed 2019-05-03 — period 2019-04-29 — 8-K
- Form 8-K — filed 2019-04-02 — period 2019-03-29 — 8-K
- Form 8-K — filed 2019-03-04 — period 2019-02-28 — FORM 8-K
- Form 8-K — filed 2019-02-05 — period 2019-01-30 — 8-K
- Form 8-K — filed 2018-12-14 — period 2018-12-13 — FORM 8-K
- Form 8-K — filed 2018-12-04 — period 2018-11-30 — FORM 8-K
- Form 8-K — filed 2018-10-31 — period 2018-10-30 — FORM 8-K
- Form 8-K — filed 2018-10-01 — period 2018-09-28 — 8-K
- Form 8-K — filed 2018-09-05 — period 2018-08-30 — 8-K
- Form 8-K — filed 2018-07-31 — period 2018-07-26 — 8-K
- Form 8-K — filed 2018-07-05 — period 2018-06-29 — FORM 8-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/orexigen-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology